Target Price | $255.50 |
Price | $235.48 |
Potential | 8.50% |
Number of Estimates | 16 |
16 Analysts have issued a price target IBM 2026 . The average IBM target price is $255.50. This is 8.50% higher than the current stock price. The highest price target is $320.00 35.89% , the lowest is $160.00 32.05% . | |
A rating was issued by 22 analysts: 11 Analysts recommend IBM to buy, 7 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the IBM stock has an average upside potential 2026 of 8.50% . Most analysts recommend the IBM stock at Purchase. |
16 Analysts have issued a sales forecast IBM 2025 . The average IBM sales estimate is $64.9b . This is 3.47% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $65.7b 4.73% , the lowest is $63.8b 1.67% .
This results in the following potential growth metrics:
2024 | $62.8b | 1.44% |
---|---|---|
2025 | $64.9b | 3.47% |
2026 | $68.1b | 4.85% |
2027 | $71.1b | 4.38% |
2028 | $76.2b | 7.16% |
2029 | $80.4b | 5.57% |
10 Analysts have issued an IBM EBITDA forecast 2025. The average IBM EBITDA estimate is $16.4b . This is 6.87% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $18.0b 17.15% , the lowest is $14.4b 6.50% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $15.4b | 3.11% |
---|---|---|
2025 | $16.4b | 6.88% |
2026 | $17.3b | 5.14% |
2027 | $18.2b | 5.61% |
2028 | $17.4b | 4.44% |
2029 | $18.4b | 5.57% |
2024 | 24.48% | 1.65% |
---|---|---|
2025 | 25.29% | 3.30% |
2026 | 25.35% | 0.24% |
2027 | 25.65% | 1.18% |
2028 | 22.88% | 10.80% |
2029 | 22.88% | 0.00% |
6 IBM Analysts have issued a net profit forecast 2025. The average IBM net profit estimate is $8.2b . This is 38.66% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $9.3b 55.61% , the lowest is $7.3b 23.52% .
This results in the following potential growth metrics and future Net Margins:
2024 | $6.0b | 21.01% |
---|---|---|
2025 | $8.2b | 38.44% |
2026 | $8.9b | 8.09% |
2027 | $9.9b | 11.14% |
2028 | $11.7b | 18.02% |
2029 | $12.7b | 8.24% |
2024 | 9.49% | 22.13% |
---|---|---|
2025 | 12.70% | 33.81% |
2026 | 13.09% | 3.07% |
2027 | 13.94% | 6.49% |
2028 | 15.35% | 10.11% |
2029 | 15.74% | 2.54% |
6 Analysts have issued a IBM forecast for earnings per share. The average IBM EPS is $8.90 . This is 38.63% higher than earnings per share in the financial year 2024. The highest EPS forecast is $9.99 55.61% , the lowest is $7.93 23.52% .
This results in the following potential growth metrics and future valuations:
2024 | $6.43 | 21.01% |
---|---|---|
2025 | $8.90 | 38.41% |
2026 | $9.62 | 8.09% |
2027 | $10.69 | 11.12% |
2028 | $12.62 | 18.05% |
2029 | $13.66 | 8.24% |
Current | 36.70 | 71.34% |
---|---|---|
2025 | 26.45 | 27.93% |
2026 | 24.47 | 7.49% |
2027 | 22.02 | 10.01% |
2028 | 18.66 | 15.26% |
2029 | 17.24 | 7.61% |
Based on analysts' sales estimates for 2025, the IBM stock is valued at an EV/Sales of 4.04 and an P/S ratio of 3.36 .
This results in the following potential growth metrics and future valuations:
Current | 4.18 | 19.43% |
---|---|---|
2025 | 4.04 | 3.46% |
2026 | 3.85 | 4.63% |
2027 | 3.69 | 4.20% |
2028 | 3.44 | 6.69% |
2029 | 3.26 | 5.28% |
Current | 3.48 | 24.56% |
---|---|---|
2025 | 3.36 | 3.36% |
2026 | 3.21 | 4.63% |
2027 | 3.07 | 4.20% |
2028 | 2.87 | 6.69% |
2029 | 2.72 | 5.28% |
Analyst | Rating | Action | Date |
---|---|---|---|
Jefferies |
Hold
➜
Hold
|
Unchanged | Mar 31 2025 |
Oppenheimer |
➜
Outperform
|
Initiated | Feb 11 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jan 30 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Jan 30 2025 |
JP Morgan |
Neutral
➜
Neutral
|
Unchanged | Jan 30 2025 |
BMO Capital |
Market Perform
➜
Market Perform
|
Unchanged | Jan 30 2025 |
Jefferies |
Hold
➜
Hold
|
Unchanged | Jan 30 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Jefferies:
Hold
➜
Hold
|
Mar 31 2025 |
Initiated
Oppenheimer:
➜
Outperform
|
Feb 11 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jan 30 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jan 30 2025 |
Unchanged
JP Morgan:
Neutral
➜
Neutral
|
Jan 30 2025 |
Unchanged
BMO Capital:
Market Perform
➜
Market Perform
|
Jan 30 2025 |
Unchanged
Jefferies:
Hold
➜
Hold
|
Jan 30 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.